News & Press

In the recent article “The DNA of a Nation,” Nature magazine highlights the highly-specialized and dedicated clinical interpretation services that Genomics England requires for their 100,000 Genomes Project, which is the first step in bringing genomics to the UK healthcare system. Omicia, the worldwide leader in genome informatics and clinical

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, today announced the completion of a $23 million Series B financing round. Several new investors participated in the round, including UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as

Omicia announces the launch of its new ACMG-scoring module for the Opal Clinical™ interpretation and reporting software platform at the 2016 ACMG Annual Clinical Genetics Meeting. This functionality provides an intuitive interface and workflow for clinical testing labs to systematically assess the disease-causing potential of genetic variants using the evidence-based

  Omicia, leading provider of clinical interpretation software and services for genetic testing labs, announced that Matt Tindall has been appointed CEO and a member of the company’s Board of Directors.  

The United Kingdom aims to sequence 100,000 human genomes by 2017. But screening them for disease-causing variants will require innovative software. For the 100,000 Genomes Project, it will use Omicia’s Opal Clinical genome interpretation software to assess which variants are likely to be causing disease.  

Rare Genomics Institute (RG) is an international non-profit that that makes cutting edge research technologies of genome sequencing, physicians and scientists around the world accessible to rare disease patients. In partnership with RG, Omicia is delighted to announce the recipients of this year’s BeHEARD Rare Disease Science Challenge, who will

Genomics England announce that it will be using technology co-developed in a partnership between Omicia and the University of Utah, and exclusively commercialized through Omicia, to interpret the DNA of Britons as part of the 100,000 Genomes Project, a national effort to hasten creation of diagnostics and treatments that are

Omicia, the leading clinical genomics company, today announced that it has been selected by Genomics England to provide clinical interpretation services for the 100,000 Genomes Project. For the first phase of the project Illumina will provide sequencing services, while Omicia will provide interpretation and clinical reports.

Genomics England has selected Omicia to interpret genomic data for the first phase of the UK’s 100,000 Genomes Project.

Omicia is recognized as one of the most innovative startup companies poised to change healthcare.